Hypoxia-elicited adaptations of tumor cells are essential for tumor growth and cancer progression. Although ample evidence exists for a positive correlation between hypoxiainducible factors (HIFs) and tumor formation, metastasis and bad prognosis, the function of the HIF-a protein stability regulating prolyl-4-hydroxylase domain enzyme PHD2 in carcinogenesis is less well understood. In this study, we demonstrate that downregulation of PHD2 leads to increased tumor growth in a hormone-dependent mammary carcinoma mouse model. Tissue microarray analysis of PHD2 protein expression in 281 clinical samples of human breast cancer showed significantly shorter survival times of patients with low-level PHD2 tumors over a period of 10 years. An angiogenesis-related antibody array identified, amongst others, amphiregulin to be increased in the absence of PHD2 and normalized after PHD2 reconstitution. Cultivation of endothelial cells in conditioned media derived from PHD2-downregulated cells resulted in enhanced tube formation that was blocked by the addition of neutralizing anti-amphiregulin antibodies. Functionally, amphiregulin was regulated on the transcriptional level specifically by HIF-2 but not HIF-1. Our data suggest that PHD2/HIF-2/amphiregulin signaling has a critical role in the regulation of breast tumor progression and propose PHD2 as a potential tumor suppressor in breast cancer.
Introduction
Hypoxia is a characteristic feature of most solid tumors, contributes to the malignant phenotype and is associated with resistance to therapies and poor prognosis (Brown and Wilson, 2004; Pouysse´gur et al., 2006) . Adaptive cellular responses to hypoxia are mainly mediated by heterodimeric hypoxia-inducible transcription factors (HIFs) and many HIF target genes are involved in cancer progression (Wenger, 2002; Semenza, 2003; Wenger et al., 2005) . On the molecular level, HIF-a protein stability and transactivation activity are regulated by oxygen-dependent hydroxylation of specific prolyl and asparaginyl residues. The HIF prolyl-4-hydroxylase domain proteins, PHD1, 2 and 3 are responsible for normoxic HIF-a proteolysis. Prolyl-4-hydroxylation is necessary for the interaction with the von Hippel-Lindau tumor suppressor protein (pVHL) that mediates HIF-a degradation (Maxwell et al., 1999; Bruick and McKnight, 2001; Epstein et al., 2001; Jaakkola et al., 2001; Ivan et al., 2002) .
Although HIF-a overexpression is found in most human cancers (Zhong et al., 1999) and correlates with poor prognosis and resistance to treatment (Aebersold et al., 2001) , the role of PHDs in tumor formation remains incompletely understood. Tumor suppressor functions have been proposed for PHD1 as well as PHD3, whereas both tumor promoting as well as suppressing effects have been reported for PHD2. Ectopic expression of PHD1 in colon carcinoma cells inhibited tumor growth and correlated with increased necrosis and decreased microvessel density in a mouse xenograft model (Erez et al., 2003) . PHD3 was found to be downregulated in colorectal cancer cells and correlated with higher tumor grade and metastasis (Xue et al., 2010) and loss of PHD3 was associated with the development of pheochromocytomas by acting downstream of c-Jun-mediated apoptosis (Lee et al., 2005) . PHD2 has been reported to induce senescence in endometrial cancer cells by regulating HIF-mediated signal transduction pathways (Kato et al., 2006) . On the other hand, increased expression levels of PHD2 have been shown to be associated with an aggressive phenotype in head and neck squamous cell carcinoma (Jokilehto et al., 2006) . Overexpression of all three PHDs and the asparaginyl hydroxylase factor inhibiting HIF correlated with tumor aggressiveness and higher rate of recurrence in pancreatic endocrine tumors (Couvelard et al., 2008) . In addition, a biphasic model for the relationship between PHD2 and tumor-forming potential has been suggested: small decreases of PHD2 led to malignant transformation of non-tumorigenic fibroblasts, whereas strongly decreased PHD2 levels did not (Lee et al., 2008) . In summary, the function of PHDs in cancer remains incompletely understood. Current data suggest that they can be functionally inactivated, genetically mutated and epigenetically downregulated in cancer and additional tissue-specific factors might impinge on PHD regulation.
In this study, we have studied the function of PHD2 in a mammary carcinoma model and demonstrate that PHD2 downregulation promotes tumor growth. In clinical samples, low-PHD2 protein expression levels correlated significantly with shorter survival times of breast cancer patients. We confirmed PHD2-dependent vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8) modulation and identified amphiregulin to be induced by loss of PHD2 and normalized by PHD2 reconstitution, suggesting that amphiregulin contributes to breast cancer progression.
Results

Increased tumor progression by PHD2 downregulation
To investigate the role of PHD2 in tumor development, stable PHD2 knockdown clones and non-targeting control clones were generated in human breast carcinoma MCF-7 cells by short hairpin RNA (shRNA) interference. After selection, stable shPHD2 clones C1 and B1 were further analyzed by reverse transcriptase quantitative PCR (RT-qPCR). Both clones showed efficient PHD2 mRNA downregulation under normoxic as well as prolonged hypoxic conditions (Figure 1a) , whereas PHD1 and PHD3 mRNA levels were not significantly altered (data not shown). HIF-1a, HIF-2a and ARNT mRNA levels slightly varied under the conditions analyzed, but were not significantly affected by PHD2 downregulation (Figure 1a ). Parental MCF-7 and control shRNA-transfected cells differed neither on the PHD2 mRNA ( Figure 1a ) or protein (Supplementary Figure S1 ) level, nor in proliferation or morphology (data not shown). Thus, both cell lines were subsequently used as controls. Immunoblot analysis confirmed efficient PHD2 knockdown in C1 and B1 clones also under prolonged hypoxic, that is, PHD2 inducing conditions (Figure 1b) . Stabilization of normoxic HIF1a and increased hypoxic accumulation of HIF-2a protein was observed in PHD2-downregulated MCF-7 cells (Figures 1b and 2b, respectively) . In clone C9, the less efficient downregulation of PHD2 correlated with reduced normoxic HIF-1a stabilization when compared with the clones C1 and B1 (Figure 1b) . Normoxic HIFa protein accumulation in shPHD2 cells is less pronounced than in hypoxic control cells, indicating that additional factors might contribute to the normoxic regulation of HIF-a subunits in To analyze the function of PHD2 in tumor formation in vivo, athymic nude mice were subcutaneously injected with parental and PHD2 knockdown MCF-7 cells. Because MCF-7 proliferation is estrogen dependent (Supplementary Figure S2) , estrogen-releasing pellets were subcutaneously implanted into mice before the injection of MCF-7 cells. Tumor growth of PHD2-downregulated MCF-7 cells in vivo was significantly increased when compared with control cells (Figure 1c , left panel). Importantly, differences in tumor growth were independent of unequal intrinsic proliferation potentials, as parental and shPHD2 MCF-7 cells showed comparable growth rates and viability in vitro (Figure 1c, right panel) . Tumor growth was analyzed over a time period of 60 days. Thereafter, sustained in vivo PHD2 suppression was confirmed on the mRNA as well as on the protein levels (Supplementary Figure  S3) . Recently, it has been proposed that heterozygous endothelial Phd2 deficiency stabilizes tumor vasculature and inhibits metastasis (Mazzone et al., 2009) . Although tumors in our model were wild type for Phd2 in hostderived endothelial cells, we did not observe metastasis in mice subcutaneously injected with shPHD2 cells. Because MCF-7 are poorly invasive breast cancer cells, we injected these cells also intravenously but still detected no incidence of metastasis, even by RT-qPCR analysis of lung samples using human PHD2-specific primers (data not shown).
Analysis of PHD2 protein expression using a tissue micro array (TMA) of 281 human breast cancer patient samples showed predominantly a diffuse and fairly homogenous cytoplasmic immunoreactivity in invasive breast cancer cells and no membraneous staining. Low or very high PHD2 levels were observed in 82 and 199 cases, respectively (Figure 1d , left panel). Apart from a significant association of low PHD2 levels with a postmenopausal status, no other associations with clinicopathological parameters were found (Supplementary Table 1 ). Univariate survival analysis by the KaplanMeier method showed significantly shorter survival times of patients with tumors having low PHD2 levels (10 years survival rates: 52 vs 67%, P ¼ 0.026; Figure 1d , right panel). In a probatory multivariate Cox analysis (including tumor grades pT, pN, G) of estrogen receptor and PHD2, PHD2 failed to demonstrate independent prognostic significance (data not shown). To confirm the specificity of the anti-PHD2 antibody, parental MCF-7 and shPHD2 C1 cells were pelleted and embedded in paraffin for immunohistochemical detection of PHD2 protein expression using the same conditions as for the TMA experiments (Supplementary Figure S4) .
Overexpression of PHD2 in shPHD2 cells suppresses tumor growth
To exclude that shRNA off-target effects increased the tumor growth in shPHD2 MCF-7 clones, we reconstituted the expression of PHD2 in the stable shPHD2 clone C1. Immunoblot analysis showed constitutively elevated PHD2 protein levels under normoxic as well as hypoxic conditions in the selected reconstituted clones no. 1 and no. 2 (Figure 2a ). PHD2 reconstitution also reduced normoxic HIF-1a protein levels and attenuated hypoxic HIF-2a accumulation (Figure 2b ). Although PHD2 expression was higher in both reconstituted clones than in parental MCF-7 cells, no difference in in vitro proliferation rates and viability was observed (data not shown). Implantation of PHD2-reconstituted and parental MCF-7 cells into athymic nude mice resulted in tumors in 13.6 and 77.3% of all cases, respectively. In addition, the three successfully grown tumors of PHD2-reconstituted cells showed a significantly decreased volume compared with tumors derived from parental MCF-7 cells (Figure 2c ). Subsequent tumor tissue analysis confirmed increased PHD2 expression in reconstituted compared with parental cells, suggesting that PHD2 overexpression leads to suppression of tumor growth (Figure 2d ).
PHD2 suppression increases tumor angiogenesis and modulates secreted angiogenic factors Tumor vascularization of experimental tumors derived from parental and shPHD2 MCF-7 cells was analyzed by PECAM-1 immunostaining. Knockdown of PHD2 resulted in a more elaborated and denser vascular network ( Figure 3a) . Quantitative analysis revealed a significant increase in vessel density, area and diameter in shPHD2 compared with parental cells (Figure 3b ). Tumors derived from parental or shPHD2 MCF-7 cells showed no obvious morphological differences by hematoxylin/eosin staining (data not shown).
To investigate a possible regulation of secreted angiogenic factors by altered PHD2 levels, we incubated human angiogenesis arrays with conditioned media of parental, shPHD2 or reconstituted PHD2 MCF-7 cells. To eliminate potential clonal differences between maternal and shPHD2 cell lines, we also used pools of lentivirally transduced shPHD2 MCF-7 cells (Supplementary Figure S5 ). Compared with conditioned media of parental MCF-7 and reconstituted PHD2 cells, VEGF was increased in shPHD2 cells, suggesting activation of the HIF pathway (Supplementary Figure  S6) . In addition, IL-8 as well as amphiregulin was elevated in the absence of PHD2, whereas reduced in PHD2-and HIF-2-dependent regulation of amphiregulin MR Bordoli et al cells overexpressing PHD2 when compared with parental MCF-7 cells. Recently, IL-8 has been shown to be induced by PHD2 downregulation in a HIF-independent but nuclear factor-kB (NF-kB)-dependent manner (Chan et al., 2009) , confirming the relevance of our experimental approach. However, amphiregulin induction by PHD2 downregulation has not been described previously.
Other pro-angiogenic factors abundantly secreted by MCF-7 cells include insulin-like growth factor binding protein 2, matrix metallopeptidase 9 and tissue inhibitor of metalloproteinase 1. However, secretion of these factors was independent of PHD2 (Supplementary Figure S6 ).
PHD2 regulates amphiregulin-dependent tube formation in vitro
To elaborate the PHD2-dependent function of amphiregulin in more detail, we performed tube formation assays in vitro. Incubation of HUVEC cells with supernatant of parental MCF-7 cells resulted in moderate tube formation ( Figure 3c ). In contrast, after PHD2 downregulation tube formation was significantly increased as determined by counting branch points and estimating total tube network length. Conversely, tube formation was markedly decreased by shRNA-mediated downregulation of amphiregulin gene expression (Figure 3c ), already following amphiregulin transcript level repression by only approximately 50% (Supplementary Figure S7 ). Importantly, stimulation of tube formation by supernatants of shPHD2 MCF-7 cells was significantly reduced by pre-incubation with a neutralizing anti-amphiregulin antibody (Figure 3d) , suggesting that the PHD2-mediated increase in tube formation was at least partly mediated by amphiregulin secretion.
Amphiregulin transcription is regulated by PHD2
Analysis of amphiregulin mRNA levels in MCF-7 cells by RT-qPCR demonstrated increased amphiregulin transcript levels after PHD2 suppression and reduced amphiregulin mRNA levels after PHD2 overexpression (Figure 4a ). Transfection of a firefly luciferase reporter gene driven by the amphiregulin gene (AREG) promoter (pAREG) into parental, shPHD2 or reconstituted MCF-7 cells resulted in relative luciferase activities recapitulating the regulation of the endogenous amphiregulin transcript levels in these cell lines (Figure 4b ). In contrast to the known hypoxia-inducible gene carbonic anhydrase 9 (CA9), amphiregulin mRNA levels were not induced under hypoxic conditions (Figure 4c ), indicating that amphiregulin regulation might be independent of the prolyl-4-hydroxylase enzymatic function of PHD2. Moreover, pharmacologic inhibition of PHD hydroxylase function using the pan-PHD inhibitor DMOG, did not induce amphiregulin expression, whereas CA9 and PHD2 were increased as expected (Supplementary Figure S8) .
To analyze the function of PHD2 on amphiregulin transcription in more detail, we transfected shPHD2 MCF-7 cells with pAREG reporter plasmids (depicted in Figure 4d ) together with active (PHD2) or inactive hydroxylase mutant PHD2. All pAREG reporter plasmids were similarly responsive to PHD2 coexpression, irrespective of the presence of the putative HIFbinding site and functional PHD2 hydroxylase activity (Figure 4e, left panel) . As expected, the HIF-dependent reporter plasmid pH3SVL (Wanner et al., 2000) responded to wild type but not mutant PHD2. Hypoxic exposure only marginally induced pAREG reporter activity and the repressive effect of PHD2 coexpression was preserved at reduced oxygen concentration ( Figure 4e , right panel). Note that pH3SVL was strongly induced by hypoxia and PHD2 reconstitution less efficiently reduced pH3SVL reporter activity under hypoxic than normoxic conditions. In conclusion, these data are all consistent with the notion that PHD2 represses amphiregulin transcription in a hydroxylaseindependent manner.
Cyclic AMP response element (CRE)-binding protein-dependent regulation of amphiregulin gene expression has been reported in the intestinal epithelial cells and a functional CRE has been identified in the human amphiregulin promoter (Plowman et al., 1990; Lee et al., 1999; O'Reilly et al., 2006) . To delineate the function of CRE-binding protein in PHD2-dependent pAREG regulation, we cotransfected shPHD2 MCF-7 cells with wild-type or mutant CRE pAREG reporter plasmids together with active or mutant PHD2. Although pAREG reporter activity was reduced on CRE site mutation, the wild-type and mutant PHD2 repressive effect were preserved (Figure 4f, left panel) . The HIFdependent reporter plasmid pH3SVL was again used as control (Figure 4f, right panel) .
Whereas functional NF-kB-binding sites in the angiogenin as well as IL-8 promoters have been reported to be required for tumor necrosis factor-a-mediated induction of reporter gene expression (Chan et al., 2009) , amphiregulin mRNA levels were neither induced by tumor necrosis factor-a treatment (Supplementary Figure S9) nor suppressed by small interfering RNA (siRNA)-mediated downregulation of the NF-kB subunit RelA (Supplementary Figure S10) . These data suggest that the signaling pathway involved in the PHD2-dependent control of amphiregulin expression in mammary carcinoma cells is different from the signaling pathway reported for PHD2-and NF-kB-dependent regulation of angiogenin and IL-8 in colon carcinoma cells (Chan et al., 2009 ).
HIF-2a-specific regulation of amphiregulin gene expression Downregulation of PHD2 in MCF-7 cells resulted in a slight normoxic accumulation of both HIF-1a and HIF-2a protein levels (Figure 5a ). Even though amphiregulin transcriptional regulation was independent of PHD2 hydroxylase function, we hence investigated whether amphiregulin expression might additionally be regulated in a HIF-a isoform-specific manner. Therefore, stable shHIF-1a and shHIF-2a MCF-7 pool of clones were generated (Figure 5b , left panel) and analyzed for amphiregulin gene expression by RTqPCR (Figure 5b, right panel) . Compared with parental cells, transcript levels of amphiregulin were upregulated in shHIF-1a and decreased in shHIF-2a MCF-7 cells, indicating that HIF-2a is mainly responsible for the regulation of amphiregulin gene expression. As evidenced by immunoblot analysis (Figure 5b , left panel), increased amphiregulin mRNA levels in shHIF1a cells might probably be due to higher HIF-2a levels in these cells. Conversely, overexpression of HIF-2a in parental MCF-7 cells increased amphiregulin promoter- 0 -Regulatory elements are labeled relative to the transcriptional start site (TSS). Two putative consensus HIF binding sites (HBS) are indicated in capital letters. (e) A measure of 200 ng pAREG reporter constructs as indicated were cotransfected with either 800 ng wild-type PHD2 or a hydroxylase-deficient PHD2 mutant (mtPHD2), and relative luciferase activities were quantified. The HIF-dependent reporter plasmid pH3SVL served as control. (f) The indicated plasmids were cotransfected as mentioned above (e). dep., dependent; Rec., reconstituted, Rel., relative. *Po0.05, **Po0.01. dependent reporter gene activity, whereas exogenous expression of HIF-1a had no effect (Figure 5c, left panel) . A PHD2 promoter-driven, that is, HIF-dependent, reporter plasmid was used to control for efficient HIF-1a and HIF-2a expression (Figure 5c, right panel) .
To analyze the function of HIF-2 in amphiregulin promoter regulation, we used again the pAREG reporter constructs depicted in Figure 4d and cotransfected them into MCF-7 shHIF-2a cells together with either HIF-2a or an empty expression vector. All pAREG reporter plasmids were induced by exogenous HIF-2a expression, irrespective of the presence of the putative HIF-binding site (Figure 5d ). The promoter-less reporter backbone pGL2 served as negative control. and HIF-2a protein levels were determined by immunoblotting (left panel) and amphiregulin mRNA levels were measured in parental, shHIF-1a and shHIF-2a MCF-7 cells (right panel). (c) MCF-7 parental cells were cotransfected with the amphiregulin promoter construct pAREG(À640/ þ 120) together with either an empty, HIF-1a or HIF-2a expression vector. Cells were cultured under normoxic or hypoxic conditions for 24 h and relative luciferase activities quantified. A PHD2 promoter-driven reporter plasmid was used as a control. (d) MCF-7 shHIF-2a cells were cotransfected with 200 ng pAREG reporter construct as indicated together with either 800 ng HIF-2a or empty expression vector, and cultured under normoxic conditions. Promoterless pGL2basic served as negative control. Transcript levels of HIF-1a, HIF-2a, amphiregulin and CA9 were analyzed in shPHD2/shHIF-1a (e) and shPHD2/siHIF-2a (f) MCF-7 cells by RT-qPCR. dep., dependent; Rel., relative.
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Finally, either HIF-1a or HIF-2a was downregulated in shPHD2 MCF-7 cells and endogenous gene expression was analyzed by RT-qPCR. HIF-1a suppression upregulated amphiregulin mRNA levels (Figure 5e ), probably indirectly because of elevated HIF-2a gene expression as previously observed on the protein level in stable HIF-1a knockdown cell pools (Figure 5b) . In contrast, HIF-2a suppression downregulated amphiregulin mRNA levels and did not influence HIF-1a gene expression (Figure 5f ). CA9 served as positive control and seems to be a HIF-1-specific target gene. In conclusion, these data indicate that amphiregulin transcription is regulated by HIF-2 independent of the putative HIF-binding site in the promoter region.
Discussion
Although the role of HIFs in tumor formation and metastasis is well known, the function of regulators of HIF-a stability during neoplastic growth has come into focus only recently. We report in this study that PHD2 functions as a tumor suppressor in xenografted tumors derived from breast carcinoma MCF-7 cells and clinical data indicate that high PHD2 protein levels are a positive prognostic survival factor in human mammary carcinomas. Mechanistically, amphiregulin contributed to PHD2 regulated in vitro tube formation and amphiregulin transcription was increased specifically by HIF-2 in breast carcinoma MCF-7 cells.
During progression of our analysis, RNA interference-mediated downregulation of PHD2 has recently been used to further elucidate the function of PHD2 in tumor formation. Wu et al. (2008) observed elevated in vivo angiogenesis of tumors derived from PHD2-silenced NIH3T3 cells and this phenotype was attributed to HIF-mediated increased expression of the pro-angiogenic VEGF and fibroblast growth factor-2. Evidence for a tumor suppressive function of PHD2 has recently also been reported by Chan et al. (2009) . PHD2 downregulation increased normoxic NF-kB activity, leading to a HIF-independent elevated secretion of the proangiogenic factors IL-8 and angiogenin in a colon carcinoma cell model. Immunohistochemical analysis of PHD2 protein levels in human breast cancer samples showed that 6 out of 11 patient samples had higher levels of PHD2 in normal tissue than in matched tumor samples (Chan et al., 2009) . Our analysis of ten years survival rates from 281 clinical mammary carcinoma samples revealed significantly enhanced survival times of patients having tumors with high PHD2 levels, supporting the proposed tumor suppressing role of PHD2. Although high PHD2 transcript levels have been reported in estrogen receptor-negative and human epidermal growth factor receptor-2 (HER2)-negative breast carcinoma (Zhang et al., 2009) , we found a significant association of low PHD2 levels with a postmenopausal state but not with tumor grades, estrogen receptor, progesteron receptor or HER2. Clinicopathological data from our cohort were collected before the broad introduction of aromatase inhibitors for postmenopausal women, but association of PHD2 with postmenopausal state might still be explained by estrogen receptor status alteration, because PHD2 correlated with fatty acid synthase, another marker of postmenopausal status. In tumor angiogenesis, PHD2 levels have to be considered not only in cancer cells but also in stromal cells. Indeed, endothelial PHD2 levels have been reported to dramatically affect tumor growth by influencing intratumoral vessel development (Mazzone et al., 2009) . In summary, accumulating evidence suggests an important regulatory role of PHD2 in tumor angiogenesis.
Amphiregulin is a heparin-binding glycoprotein that has originally been isolated from conditioned media of human breast carcinoma MCF-7 cells and identified as epidermal growth factor receptor ligand (Shoyab et al., 1988) . During development, amphiregulin is the most abundant epidermal growth factor-like growth factor in the pubertal mammary gland and has an important role in ductal morphogenesis (Luetteke et al., 1999) . There is clear evidence for a role of amphiregulin in breast cancer initiation as well as progression (McBryan et al., 2008; Willmarth and Ethier, 2008) . Amphiregulin is often overexpressed in mammary carcinoma (Qi et al., 1994) and generally higher in invasive breast carcinomas than in normal mammary epithelium (Panico et al., 1996) .
Importantly, amphiregulin antisense expression in a transformed human breast epithelial cell line that has been selected for its increased tumorigenicity in vivo, reversed the malignant phenotype in nude mice and led to a significant reduction in tumor mass (Ma et al., 1999) . Moreover, tumor vascularization was markedly reduced in tumors derived from amphiregulin antisense expressing cells, suggesting that amphiregulin modulates angiogenesis in these cells. Although it remains largely unknown how amphiregulin might mechanistically contribute to breast cancer pathogenesis in general, regarding angiogenesis it has been shown that amphiregulin antisense expression reduced the angiogenic factor TGFb1 (Giusti et al., 2003) and upregulated the expression of IL-8 in human airway epithelial cells (Chokki et al., 2006) . Our results showed that the in vitro tube formation potential of shPHD2 cells was signficantly increased compared with parental MCF-7 cells and again reduced after addition of neutralizing antiamphiregulin antibodies, although elevated levels of the potent angiogenic factors VEGF and IL-8 remained unchanged. This suggests that amphiregulin contributes substantially to pro-angiogenic modulation by MCF-7 breast cancer cells.
A few regulators of amphiregulin gene expression have been reported previously: EGF-related growth factors auto-and cross-induce each other (Barnard et al., 1994) , and amphiregulin transcription is induced by estrogen, probably indirectly as no estrogen-response elements have been identified in the amphiregulin promoter region (Martinez-Lacaci et al., 1995) . In fetal kidney differentiation, the zinc-finger transcription factor Wilms tumor suppressor (WT1) has been shown to regulate amphiregulin gene expression (Lee et al., 1999 ), but we did not find any WT1 expression in MCF-7 cells (data not shown). Recently, BRCA1 has been described as transcriptional repressor of amphiregulin and loss of BRCA1 resulted in elevated amphiregulin protein levels (Lamber et al., 2010) . The role of oxygen in amphiregulin regulation is incompletely understood. Whereas hyperoxia induced amphiregulin in a model of bronchopulmonary dysplasia (Wagenaar et al., 2004) , hypoxia has been reported to upregulate amphiregulin gene expression in a CRE-binding proteindependent manner in intestinal epithelial cells (O'Reilly et al., 2006) .
Our results suggest that PHD2 regulates amphiregulin on the transcriptional level, directly or indirectly involving HIF-2 but not HIF-1 (a schematic overview is shown in Supplementary Figure S11) . Intriguingly, although HIF-2 clearly increased endogenous amphiregulin mRNA levels and exogenous amphiregulin promoter activity, cultivation of MCF-7 cells under hypoxic conditions did not significantly regulate endogenous amphiregulin transcript levels or promoter activity. These data suggest that normoxic, basal HIF-2 levels are sufficient for amphiregulin gene expression which is not further induced by hypoxic stabilization of HIF-2a. Supporting this hypothesis, it has been shown that HIF-2 is slightly more abundant in normoxic and mildly hypoxic cells than HIF-1 (Wiesener et al., 1998) and a recent report demonstrated that the HIF-2-specific target gene, CITED2, was maximally expressed under normoxic conditions (Franovic et al., 2009) . Furthermore, it has been shown that the vascular endothelial-cadherin gene is not regulated by hypoxic conditions, but the vascular endothelial-cadherin promoter is nevertheless activated by HIF-2 together with the Ets-1 transcription factor (Le Bras et al., 2007) .
Several groups reported on the role of PHDs in regulating in vivo angiogenesis. Conditional knockout of PHD2, but not PHD1 or PHD3, resulted in increased secretion of VEGF and enhanced angiogenesis (Takeda et al., 2007) and application of pan-PHD inhibitors in rats led to HIF-a stabilization and stimulated angiogenesis (Warnecke et al., 2003) . As PHD inhibitors have been developed to treat ischemic diseases, concerns might arise about adverse effects of these inhibitors in tumor progression. Our study demonstrates that PHD2 has a critical role in tumor progression, suggesting that a combinatory treatment regimen of PHD inhibitors together with antiangiogenic compounds or, if available, anti-HIF-a isoform-specific inhibitors, might be required to avoid the induction of potentially tumor promoting signaling pathways.
Materials and methods
Plasmids
Cloning of PHD2 expression vectors and other plasmids was carried out using Gateway technology (Invitrogen, Basel, Switzerland) as described previously (Barth et al., 2007) .
Cell culture and transfections
Human MCF-7 breast carcinoma cells were cultured in highglucose Dulbecco's modified Eagle's medium (Sigma, Buchs, Switzerland) as described previously (Camenisch et al., 1999) . HUVEC cells were kindly provided by TF Lu¨scher (Zu¨rich, Switzerland) and cultured in complete endothelial basal medium-2 containing 2% fetal calf serum (Lonza, Basel, Switzerland) . For long-term hypoxia, cells were grown in a gas-controlled glove box (InvivO 2 400, Ruskinn Technologies, Leeds, UK). Transfections were performed using polyethylenimine (Polysciences, Warrington, PA, USA) as described previously (Stiehl et al., 2006) .
Immunoblotting
Immunoblot analyses were performed as previously described (Balamurugan et al., 2009) . Antibodies used were mouse monoclonal antibody (mAb) anti-HIF-1a (Transduction Laboratories, BD Biosciences, Allschwil, Switzerland), anti-HIF-2a (Novus Biologicals, LuBioScience, Lucerne, Switzerland), mAb anti-V5 (Invitrogen), mAb anti-b-actin (Sigma), rabbit polyclonal anti-PHD2 antibody (Novus), mAb anti-PHD3 was kindly provided by PJ Ratcliffe (Oxford, UK).
Reporter gene assays
Construction of the HIF-dependent firefly luciferase reporter gene construct pH3SVL was described previously (Wanner et al., 2000) . The amphiregulin promoter plasmid pAREG (À641/ þ 120) was kindly provided by SB Lee (Bethesda, USA) (Lee et al., 1999) . Truncations of this plasmid have been constructed by PCR and recombinant cloning techniques. As sequencing revealed point mutations in the parental plasmid, the (À120/ þ 120) region was de novo cloned from MCF-7 genomic DNA. The consensus CRE site (5 0 -TGACGTC-3 0 ) in pAREG(À120/ þ 120), located 65 nucleotides upstream of the transcriptional start site, was mutated to (5 0 -TGAaaTC-3 0 ) by site-directed mutagenesis. The PHD2 luciferase reporter plasmid pP2P(À603/ þ 3)wt is a truncated version of the previously published human PHD2 promoter (Metzen et al., 2005) . Cells were cotransfected with 200 ng reporter plasmid and 10 ng pRLSV40 Renilla luciferase reporter vector (Promega, Du¨bendorf, Switzerland) and luciferase reporter gene activity was determined using the dual-luciferase reporter assay system according to the manufacturer's instructions (Promega).
mRNA quantification
Total cellular RNA was extracted as described previously (Barth et al., 2007) . First-strand complementary DNA synthesis was performed with 1-5 mg total RNA using reverse transcriptase and mRNA levels were measured by real-time quantitativePCR using a SybrGreen qPCR reagent kit (Sigma) in combination with the MX3000P light cycler (Stratagene, Amsterdam, The Netherlands). To verify RNA integrity and equal input levels, ribosomal protein L28 mRNA was determined, and the data were expressed as ratios relative to L28 levels.
Mice xenografts
Estrogen-releasing pellets (0.72 mg 17b-estradiol 60-days release, Innovative Research of America, Sarasota, FL, USA) were subcutaneously implanted into the neck of NMRI female nude mice (Harlan Europe, The Netherlands) 5 days before subcutaneous injection of 1-2 Â 10 7 MCF-7 cells in 200 ml phosphate-buffered saline. Tumors were measured using a caliper every 3 days. Animal experimentation was approved by the veterinary office of the Kanton Zu¨rich (approval number 04/2008).
Tissue specimen and TMA analysis For immunohistochemistry, our study included TMAs of 281 invasive breast cancer cases diagnosed at the Institute of Surgical Pathology (University Hospital, Zu¨rich, Switzerland) as described (Theurillat et al., 2007) . Tumor histology was determined according to the criteria of the World Health Organization (2003), whereas disease stage was assessed according to the International Union Against Cancer (UICC, 2002) . Tumors were graded according to Bloom and Richardson, as modified by Elston and Ellis (1993) The clinicopathological characteristics of the patients/tumors are described in Supplementary Table 1 . Patient age at the time of diagnosis ranged from 26 to 98 years with a median of 61 years (mean 62). For statistical analysis, only cases with clinical follow-up data were considered. The median observation time for overall survival was 61 months for patients still alive at the time of analysis. In all, 74 patients (27%) died during follow-up. Data on adjuvant therapy was not available. PHD2 expression was semiquantitatively scored as low or high.
Statistical analysis
Where not otherwise indicated, results are presented as mean values ± standard error of the mean of at least n ¼ 3 independent experiments. P-values were obtained by unpaired t-tests (*Po0.05, **Po0.01, ***Po0.001). For statistical TMA analysis, PHD2 expression data were analyzed in crosstables with w 2 -test. Survival analysis was conducted according to Kaplan-Meier with log rank test and multivariate Cox regression analysis (inclusion model). All statistics were calculated using PASW (SPSS 18) software.
Immunohistochemistry
Dissected tumors were macroscopically evaluated, cut in half, and frozen in embedding medium (Tissue-Tek OCT compound, Sakura Finetek, Staufen, Germany). Acetone-fixed cryosections (8 mm) were blocked with 0.5% bovine serum albumin and incubated with anti-PECAM-1 antibody (BD Biosciences) for 1 h at room temperature to stain blood vessels. Tumor sections were further incubated with Alexa 568-conjugated goat anti-rat antibodies (Invitrogen) followed by nuclear staining with 4,6-diamidino-2-phenylindole and mounting in Prolong medium (Invitrogen). Blood vessel density, area and size were quantified using Axio Vision software (Carl Zeiss, Feldbach, Switzerland) . TMA sections were processed using an automated immunohistochemistry platform (Benchmark, Ventana, Roche, Illkirch, France) with a PHD2 polyclonal anti-PHD2 antibody at 1:100 dilution (NB100-137; Novus Biologicals).
shRNA constructs and lentiviral infections Expression vectors encoding shRNA sequences targeting human PHD2, HIF-1a, HIF-2a and amphiregulin driven by the U6 promoter in a pLKO.1-puro plasmid were purchased from Sigma. Variants of shRNA expression plasmids bearing a hygromycin resistance marker were generated by replacing the original puromycin resistance cassette in pLKO.1. Viral particles were produced in HEK293T cells using the ViraPower lentiviral expression system according to the manufacturer's instructions (Invitrogen).
RNA interference MCF-7 cells were transfected with 100 nM siRNA duplex oligonucleotides using Lipofectamine 2000 (Invitrogen). The following RNA interference sequences (Invitrogen) were used: control siRNA, forward 5 0 -GCUCCGGAGAACUACCAG AGUAUUA-3 0 ; HIF-2a siRNA, forward 5 0 -CAGGUGGA GCUAACAGGACAUAGUA-3 0 ; RelA siRNA, forward 5 0 -AUCCGGUGACGAUCGUCUGUAUCUG-3 0 .
Proteome profiler Cells (1.2 Â 10 6 ) were incubated for 48 h in Dulbecco's modified Eagle's medium containing 10% fetal calf serum. Supernatants were harvested and treated according to manufacturer's protocol (Human Angiogenesis Array kit, R&D Systems Europe, Abingdon, UK). Proteome profiler arrays were carried out in triplicates and data are presented as ratios relative to the positive controls.
Tube formation assay Cells (1 Â 10 5 ) were incubated for 48 h in endothelial basal medium-2 medium containing 2% fetal calf serum and supernatants were harvested. HUVEC cells (7.5 Â 10 3 ) were resuspended in 50 ml conditioned medium and plated into the wells of Angiogenesis m-slides (Ibidi, Vitaris, Baar, Switzerland) coated with 3 mg/ml Matrigel (BD Biosciences). Tube formation was photographed after 6 h. Quantification was performed either by counting the branching points, defined as a vessel that subdivides in at least two additional vessels, or by measuring the length of the tubes using Axio Vision software (Carl Zeiss).
